Healthcare technologies manufacturer Valeritas Holdings, Inc. announced on Tuesday good benefits from a pre-clinical pharmacokinetic (PK) study involving the subcutaneous delivery of cannabidiol (CBD) applying the company’s proprietary h-Patch device.
The h-Patch is a wearable, disposable drug delivery device that is made to provide injectable medicines into the fatty subcutaneous tissue beneath the dermis layer of skin.
For the study, the h-Patch was made use of to provide two CBD regimens, 40mg and 76mg, more than 24-hours with PK evaluated at different time points out to 48 hours from the commence of infusion.
Each dosages showed speedy absorption and distribution with detectable levels of CBD displaying in blood a single hour immediately after the starting of the infusion.
“This study highlights Valeritas’ partnering possibilities to leverage the h-Patch technologies beyond insulin delivery,” stated Valeritas President and CEO John Timberlake in a statement. “Subcutaneous infusion is a effective delivery system for a selection of drugs with solubility, permeability, and initial-pass metabolism challenges, and the h-Patch may possibly offer you a price-productive option suggests of dependable and patient-friendly drug dosing.”
According to Valeritas, orally-delivered CBD options have a low bioavailability which ranges from six-10 %.
Valeritas believes that subcutaneous CBD delivery could hold several positive aspects more than oral dosing, which includes prolonged half-life, minimization of variation in CBD metabolism in the basic population, and the potential to realize therapeutic concentrations with smaller sized doses—features which could lead to a lot more dependable, uniform dosing.